The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Purpose To investigate the prognostic value of tumor-infiltrating regulatory T cells (Tregs) in the distribution of cancer nest, cancer stroma and normal mucosa and FOXP3-positive cancer cells in colon cancer patients after resection. Methods Paraffin blocks of operation resection of primary adenocarcinoma of colon were obtained from ninety patients. The distribution of tumor-infiltrating Tregs was detected by tissue microarray and immunohistochemistry staining technique to evaluate the prognostic effects by Kaplan-Meier and Cox regression analysis using median values as cutoff. Results The intratumoral Tregs counts were significantly higher than that in corresponding normal mucosa tissues (P Conclusions The higher tumor-infiltrating Tregs counts are closely associated with the improved prognostic effects of colon carcinoma. Tregs play different roles in cancer nest and cancer stroma. And the appearance of Tregs in cancer nest is a promising independent risk factor for overall survival in colon carcinoma. FOXP3-positive cancer cells may also be a risk factor for overall survival in colon carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [143]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608 · cited 1×
“In particular the regulatory T cells (Tregs), these cells were first reported by (Sakaguchi et al. 1995) in both mice and humans as a key contributor to the maintenance of immunological tolerance and the prevention of autoimmunity.”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 2×
“This finding seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor…”
BackgroundResultFOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439 · cited 2×
“tumor immune response by influencing the effect of CD4? and CD8? T cells, NK cells and myeloid cells, through different mechanisms (Sakaguchi et al. 2010).”
BackgroundEffector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200 · cited 2×
“And a series of studies have revealed that the high tumor-infiltrating Tregs counts often associate with a poor prognosis in breast (Bates et al. 2006), ovarian (Curiel et al.”
BackgroundGao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110 · cited 3×
“This finding seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor…”
BackgroundResultHori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,066
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Interleukin-17 promotes angiogenesis and tumor growth
Numasaki, M. (2003) · Blood · doi:10.1182/blood-2002-05-1461 · Cited by 834 · cited 2×
“This can stimulate angiogenesis through VEGF production and induce inflammatory reaction triggered by cytokines like IL-17, IL-1, IL-6 and TNF-a, with subsequent proangiogenic (Numasaki et al. 2003) and tumor-enhancing effects (Bromberg and Wang 2009), thus contributing to the progress of tumor.”
BackgroundHiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831 · cited 3×
“This finding seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor…”
BackgroundResultInflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 542 · cited 2×
“2003) and tumor-enhancing effects (Bromberg and Wang 2009), thus contributing to the progress of tumor.”
BackgroundThe Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective
Galon, J., Fridman, W.-H., & Pagès, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4806 · Cited by 447 · cited 1×
“Recently, tumor immune microenvironment was reported to play an important role in the development of the tumor (Galon et al. 2007).”
BackgroundPetersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 433 · cited 3×
“…seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor prognosis.”
BackgroundResultZuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., Liu, Y., Wang, Y., Liu, X., Chan, M. W. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.034 · Cited by 395 · cited 1×
“Recent studies found that FOXP3 was not only expressed in Tregs, but also in several types of malignant tumor cells, including pancreatic (Hinz et al. 2007), breast (Zuo et al. 2007), lung (Tao et al. 2012) and prostate (Wang et al. 2009) cancers.”
BackgroundFoxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer
Hinz, S., Pagerols-Raluy, L., Oberg, H.-H., Ammerpohl, O., Grüssel, S., Sipos, B., Grützmann, R., Pilarsky, C., Ungefroren, H., Saeger, H.-D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3304 · Cited by 352 · cited 3×
“Recent studies found that FOXP3 was not only expressed in Tregs, but also in several types of malignant tumor cells, including pancreatic (Hinz et al. 2007), breast (Zuo et al. 2007), lung (Tao et al. 2012) and prostate (Wang et al. 2009) cancers.”
BackgroundFrey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333 · cited 2×
“But conclusions contrary to the previous reports in other cancers were established by recent studies in which high count of tumor-infiltration Tregs was associated with improved survival in colorectal cancer (Frey et al. 2010; Pages et al. 2005; Salama et al. 2009).”
ResultLadoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331 · cited 3×
“The reason of this discrepancy may be attributed to the existence of microbiological flora in colonic lumen which can infiltrate the tumor through the increased permeability of the physical structure of the colonic mucosal barrier (Ladoire et al. 2011a, b).”
BackgroundTao, H., Mimura, Y., Aoe, K., Kobayashi, S., Yamamoto, H., Matsuda, E., Okabe, K., Matsumoto, T., Sugi, K., & Ueoka, H. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.002 · Cited by 253 · cited 3×
“Recent studies found that FOXP3 was not only expressed in Tregs, but also in several types of malignant tumor cells, including pancreatic (Hinz et al. 2007), breast (Zuo et al. 2007), lung (Tao et al. 2012) and prostate (Wang et al. 2009) cancers.”
BackgroundJordanova, E. S., Gorter, A., Ayachi, O., Prins, F., Durrant, L. G., Kenter, G. G., van der Burg, S. H., & Fleuren, G. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4554 · Cited by 233 · cited 2×
“This finding seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor…”
BackgroundResultSomatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate
Wang, L., Liu, R., Li, W., Chen, C., Katoh, H., Chen, G.-Y., McNally, B., Lin, L., Zhou, P., Zuo, T., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.016 · Cited by 218 · cited 1×
“Recent studies found that FOXP3 was not only expressed in Tregs, but also in several types of malignant tumor cells, including pancreatic (Hinz et al. 2007), breast (Zuo et al. 2007), lung (Tao et al. 2012) and prostate (Wang et al. 2009) cancers.”
BackgroundClarke, S. L., Betts, G. J., Plant, A., Wright, K. L., El-Shanawany, T. M., Harrop, R., Torkington, J., Rees, B. I., Williams, G. T., Gallimore, A. M., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000129 · Cited by 213 · cited 2×
“Tregs have the ability to inhibit the immune response against tumors mediated by T cells in colorectal cancer (Clarke et al. 2006), which can protect the growth behavior of tumor.”
BackgroundPerrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 210 · cited 3×
“…seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor prognosis.”
BackgroundResultLadoire, S., Arnould, L., Mignot, G., Coudert, B. P., Rébé, C., Chalmin, F., Vincent, J., Bruchard, M., Chauffert, B., Martin, F., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0831-1 · Cited by 148 · cited 3×
“The reason of this discrepancy may be attributed to the existence of microbiological flora in colonic lumen which can infiltrate the tumor through the increased permeability of the physical structure of the colonic mucosal barrier (Ladoire et al. 2011a, b).”
BackgroundYoon, H. H., Orrock, J. M., Foster, N. R., Sargent, D. J., Smyrk, T. C., & Sinicrope, F. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042274 · Cited by 98 · cited 3×
“Surprisingly, seven clinical studies have showed that (Salama et al. 2009; Yoon et al. 2012), in patients bearing colorectal carcinoma, a high tumor-infiltrating Tregs counts are associated with an improved prognosis.”
BackgroundResultLi, J. F., Chu, Y. W., Wang, G. M., Zhu, T. Y., Rong, R. M., Hou, J., & Xu, M. (2009) · BJU International · doi:10.1111/j.1464-410x.2008.08151.x · Cited by 96 · cited 3×
“…seems to be consistent with other outcome studies in various human carcinomas (Curiel et al. 2004; Gao et al. 2007; Hiraoka et al. 2006; Jordanova et al. 2008; Li et al. 2009; Perrone et al. 2008; Petersen et al. 2006), in which the high accumulation of Tregs often results in a poor prognosis.”
BackgroundResultKim, M., Grimmig, T., Grimm, M. R., Lazariotou, M., Meier, E. C., Rosenwald, A., Tsaur, I., Blaheta, R. A., Heemann, U. W., Germer, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053630 · Cited by 95 · cited 2×
“In colorectal cancer, high FOXP3 expression of the cancer cells was associated with poor prognosis compared to patients with low FOXP3 expression (Kim et al. 2013).”
BackgroundResultSurvival from cancer of the uterus in England and Wales up to 2001
Cooper, N., Quinn, M. J., Rachet, B., Mitry, E., & Coleman, M. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604591 · Cited by 40
Survival from cancer of the rectum in England and Wales up to 2001
Mitry, E., Rachet, B., Quinn, M. J., Cooper, N. S., & Coleman, M. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604579 · Cited by 24 · cited 1×
“Despite improved progress that has been made in basic and clinical research, the overall survival of colorectal cancer did not improve significantly (Mitry et al. 2008).”
Background
Cited by
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
BackgroundZhao, Y., Ge, X., He, J., Cheng, Y., Wang, Z., Wang, J., & Sun, L. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1621-9 · Cited by 116
“In addition, as previously reported, only FOXP3+ Treg cell infiltration in cancer nests was associated with poor prognosis [47].”
BackgroundRelevance of Regulatory T Cells during Colorectal Cancer Development
Olguín, J. E., Medina-Andrade, I., Rodríguez, T., Rodríguez‐Sosa, M., & Terrazas, L. I. (2020) · Cancers · doi:10.3390/cancers12071888 · Cited by 89
“This was also associated with the frequency of Foxp3+ cells in patients with lymphatic invasion [53].”
Wang, Y., Li, J., Nakahata, S., & Iha, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137346 · Cited by 98
“In colorectal cancer (CRC), prognostic disparities are observed: Tregs within the tumor mesenchyme are linked to better outcomes, while those within the tumor nests and margins are associated with adverse patient prognoses [253,254].”
Background
Metadata
- Authors
- Xu, W., Liu, H., Song, J., Fu, H.-X., Qiu, L., Zhang, B.-F., Li, H.-Z., Bai, J., & Zheng, J.-N.
- Affiliations
- Affiliated Hospital of Xuzhou Medical College (CN)
- Xuzhou Medical College (CN)
- Corresponding author
- Bai, Jin
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2013-09-05
- Volume
- 139
- Issue
- 11
- Pages
- 1845-1852
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC11824243
- OpenAlex
- W2002094191
- Cited by
- 31
- References
- 31
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 2 · 2022: 1 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 2 · 2014: 1
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- regulatory T cells, colon cancer, tumor-infiltrating lymphocytes, tumor stroma, prognostic factors, overall survival, lymphatic invasion, TNM stage, tumor microenvironment
- MeSH terms
- Adenocarcinoma, Aged, Colonic Neoplasms, Female, Humans, Immunohistochemistry, Lymphatic Metastasis, Male, Neoplasm Staging, Prognosis, Risk Factors, Lymphocytes, Tumor-Infiltrating, Paraffin Embedding, Tissue Array Analysis, T-Lymphocytes, Regulatory, Forkhead Transcription Factors, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.